hydroxychloroquine has been researched along with Infant, Newborn, Diseases in 2 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Infant, Newborn, Diseases: Diseases of newborn infants present at birth (congenital) or developing within the first month of birth. It does not include hereditary diseases not manifesting at birth or within the first 30 days of life nor does it include inborn errors of metabolism. Both HEREDITARY DISEASES and METABOLISM, INBORN ERRORS are available as general concepts.
| Excerpt | Relevance | Reference |
|---|---|---|
| " hydroxychloroquine and/or prednisone) were continued during pregnancy." | 3.73 | [Perinatal consequences of maternal connective tissue diseases: a prospective study of 73 cases]. ( Costedoat-Chalumeau, N; de Montgolfier, I; Gold, F; Lapillonne, A; Renaud, C; Vautier-Brouzes, D, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Khan, MSI | 1 |
| Nabeka, H | 1 |
| Akbar, SMF | 1 |
| Al Mahtab, M | 1 |
| Shimokawa, T | 1 |
| Islam, F | 1 |
| Matsuda, S | 1 |
| Renaud, C | 1 |
| de Montgolfier, I | 1 |
| Vautier-Brouzes, D | 1 |
| Costedoat-Chalumeau, N | 1 |
| Lapillonne, A | 1 |
| Gold, F | 1 |
2 other studies available for hydroxychloroquine and Infant, Newborn, Diseases
| Article | Year |
|---|---|
Risk of congenital birth defects during COVID-19 pandemic: Draw attention to the physicians and policymakers.
Topics: Adenosine Monophosphate; Alanine; Antimalarials; Antiviral Agents; Congenital Abnormalities; COVID-1 | 2020 |
[Perinatal consequences of maternal connective tissue diseases: a prospective study of 73 cases].
Topics: Adult; Connective Tissue Diseases; Female; Glucocorticoids; Humans; Hydroxychloroquine; Infant, Newb | 2006 |